ALK and neoplasm: The rare patients (2/191 or 1%) with actionable genetic alterations (one with ALK, and one with RET fusion, Table 1) had a favorable course under TKI (death after 38 months of treatment with several ALK inhibitors as well as chemotherapy, partly published (26), and still alive with ongoing tumor response to second-line pralsetinib at 16.2 months, respectively).